TUDCA — Safety, Research, Risks & Legal Status

Not medical advice. TUDCA is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Tauroursodeoxycholic acid, tauroursodeoxycholate, TUDCA, taurine-conjugated ursodeoxycholic acid, Tudcabil (Italy brand); parent compound UDCA / ursodeoxycholic acid / ursodiol
Category	Supplement
Compound class	Hydrophilic bile acid; taurine conjugate of ursodeoxycholic acid (UDCA)
Endogenous source	Produced in small amounts when gut bacteria conjugate UDCA with taurine; historically a component of bear bile
Route	Oral
Best human evidence	Cholestatic liver disease (e.g., primary biliary cholangitis); used as a licensed drug for this abroad
Highest-profile trial use	As taurursodiol in the AMX0035 ALS combination (phase 2 positive, phase 3 PHOENIX negative; product withdrawn 2024)
US status	Not FDA-approved; sold as a dietary supplement, with FDA import alerts on bulk Chinese TUDCA powder
US legal status	In the United States TUDCA is not an FDA-approved drug. It is widely sold as a dietary supplement for "liver support," but its status as a lawful dietary ingredient is not clean: unlike its parent compound UDCA (ursodiol), which is an FDA-approved prescription drug for gallstone dissolution and primary biliary cholangitis, TUDCA has no US marketing approval, and the FDA has issued import alerts on bulk TUDCA powder from China as potentially misbranded/adulterated. It is not scheduled or otherwise controlled. Abroad, TUDCA has been marketed as a pharmaceutical for cholestatic liver disease (e.g., Tudcabil in Italy, and formulations in China and South Korea). As a taurine conjugate of UDCA, it is investigated as a drug ingredient (notably one half of the AMX0035 combination), not merely a supplement. Informational only; this is not legal or medical advice.

What is TUDCA?

TUDCA (tauroursodeoxycholic acid) is a hydrophilic bile acid, the taurine conjugate of ursodeoxycholic acid (UDCA). It occurs endogenously in humans in small amounts, produced when gut bacteria conjugate UDCA with taurine, and was historically a component of bear bile used in traditional East Asian medicine. It is marketed today as an oral supplement positioned for liver, bile-flow, endoplasmic-reticulum (ER) stress, and mitochondrial "support." Its cytoprotective interest rests on well-characterized cell and animal biology plus a small amount of human data in cholestatic liver disease and metabolic endpoints; most of the broader neuroprotective and longevity claims attached to it in the supplement market are extrapolated from preclinical models rather than robust human trials.

How it works

TUDCA is a hydrophilic, cytoprotective bile acid. Its most cited action is as a "chemical chaperone": it is proposed to stabilize protein folding in the endoplasmic reticulum, reduce ER stress, and dampen the unfolded protein response (UPR), though recent work suggests its effects extend beyond simple chaperoning. It is also anti-apoptotic, interfering with mitochondrial apoptotic signaling (reducing Bax translocation, cytochrome c release and caspase activation) and stabilizing mitochondrial membranes, which underpins the neuroprotective and hepatoprotective hypotheses. As a bile acid it can act on receptors including the farnesoid X receptor (FXR) and TGR5, and it shifts the bile-acid pool toward a less cytotoxic, more hydrophilic profile, improving bile flow in cholestasis. In the metabolic setting, reducing ER stress is the proposed route to improved hepatic insulin signaling. These mechanisms are well established in cells and animals; how much they translate to human clinical benefit outside cholestatic liver disease remains unproven.

Background & history

Ursodeoxycholic acid, TUDCA's parent, is the active principle long valued in bear bile within traditional East Asian medicine, and the taurine-conjugated form (TUDCA) is a natural constituent of that bile. In modern pharmacology UDCA (ursodiol) became an established drug for gallstone dissolution and primary biliary cholangitis. TUDCA itself was studied and marketed as a hepatobiliary drug in parts of Europe and Asia (for example Tudcabil in Italy, with roughly 898,000 tablets sold there between 1997 and 2007 without reported toxicity). Interest broadened in the 2000s and 2010s as cell and animal work identified it as a chemical chaperone and anti-apoptotic agent, spawning research in neurodegeneration, retinal disease and metabolic disease. It reached its highest clinical profile as taurursodiol, one half of AMX0035 for ALS, whose approved product Relyvrio/Albrioza was later withdrawn in 2024 after the phase 3 PHOENIX trial failed. In parallel it grew into a popular standalone liver-support and "longevity" supplement.

What the research says

Human evidence is uneven. The strongest signal is in cholestatic liver disease: small controlled and comparative studies (including in primary biliary cholangitis) found TUDCA improved liver enzymes comparably to UDCA, which is why it has been used as a licensed drug for these conditions in some countries. A small 4-week randomized study in obese, insulin-resistant subjects (Kars et al., 2010; 1,750 mg/day) reported roughly 30% improvement in hepatic and muscle insulin sensitivity but no benefit in adipose tissue, and no durable follow-up has confirmed lasting clinical benefit. In ALS, TUDCA is best known as one component of the two-drug combination AMX0035 (sodium phenylbutyrate plus taurursodiol/TUDCA): the phase 2 CENTAUR trial suggested slowed functional decline and a survival signal, but the larger confirmatory phase 3 PHOENIX trial was negative, leading the manufacturer to withdraw the approved product (Relyvrio/Albrioza) in 2024. TUDCA alone has not been shown in adequately powered trials to treat ALS, Alzheimer's, Parkinson's, retinal disease, or metabolic disease. Much of the mechanistic enthusiasm derives from cell culture and rodent models. Treat non-cholestatic uses as preliminary or preclinical.

Reported effects

Improvement in cholestatic liver enzymes (ALP, GGT) in bile-flow disorders such as PBC, supported by small human studies
Short-term improvement in hepatic and skeletal-muscle insulin sensitivity in one small 4-week study (not replicated long-term)
Reduction of endoplasmic-reticulum (ER) stress markers in cells and animal models (proposed chemical-chaperone effect)
Anti-apoptotic and anti-inflammatory effects across preclinical models (largely not confirmed as clinical outcomes in humans)
Neuroprotective signals in animal models of ALS, Parkinson's and Alzheimer's (human trials of TUDCA alone are lacking or negative)
Generally well tolerated in trials, with effects mostly limited to mild GI changes

Dosing & administration (informational)

Informational only, not a protocol. In the published human literature, oral TUDCA has been studied across a range roughly from 500 mg/day up to about 1,750-2,000 mg/day, typically divided. Cholestatic-liver studies used on the order of 500-1,500 mg/day for months; the small insulin-sensitivity study used 1,750 mg/day for 4 weeks; ALS work using the AMX0035 combination delivered TUDCA/taurursodiol at about 1 g twice daily alongside sodium phenylbutyrate, not as TUDCA monotherapy. These figures describe what appears in the literature and should not be read as a recommended dose. Peptropix does not provide dosing guidance; anyone considering TUDCA for any purpose should consult a qualified clinician who can account for their liver status, medications, and diagnosis.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Most common effects are gastrointestinal: diarrhea, loose stools, nausea, dyspepsia, bloating and mild abdominal discomfort, usually mild and transient
Long-term human safety data are limited; the best-characterized use is up to ~500-1,750 mg/day for weeks to about a year in monitored studies, not open-ended self-supplementation
Avoid in pregnancy and breastfeeding: no TUDCA-specific safety data exist, even though the related UDCA has been used in pregnancy under medical supervision
As a bile acid it alters bile composition and flow; people with biliary obstruction, active gallbladder disease, or cholestasis of unclear cause should not self-treat and need clinician evaluation
Purity is a real concern: FDA import alerts on bulk Chinese TUDCA powder mean supplement material may be mislabeled, underdosed, or contaminated
Interactions with bile-acid-binding drugs and with other hepatobiliary agents are plausible; those with liver or GI disease or on prescription medication should consult a clinician before use
Not a substitute for evaluation or treatment of any diagnosed liver disease

Drug & supplement interactions

T
U
D
C
A
h
a
s
n
o
t
b
e
e
n
t
h
e
s
u
b
j
e
c
t
o
f
c
o
m
p
r
e
h
e
n
s
i
v
e
h
u
m
a
n
d
r
u
g
-
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
,
s
o
i
n
t
e
r
a
c
t
i
o
n
c
o
n
c
e
r
n
s
a
r
e
l
a
r
g
e
l
y
i
n
f
e
r
r
e
d
f
r
o
m
i
t
s
c
l
a
s
s
.
A
s
a
b
i
l
e
a
c
i
d
,
i
t
s
a
b
s
o
r
p
t
i
o
n
a
n
d
e
f
f
e
c
t
c
a
n
b
e
b
l
u
n
t
e
d
b
y
b
i
l
e
-
a
c
i
d
s
e
q
u
e
s
t
r
a
n
t
s
(
c
h
o
l
e
s
t
y
r
a
m
i
n
e
,
c
o
l
e
s
t
i
p
o
l
,
c
o
l
e
s
e
v
e
l
a
m
)
a
n
d
b
y
a
l
u
m
i
n
u
m
-
c
o
n
t
a
i
n
i
n
g
a
n
t
a
c
i
d
s
,
w
h
i
c
h
b
i
n
d
b
i
l
e
a
c
i
d
s
i
n
t
h
e
g
u
t
.
C
o
m
b
i
n
e
d
u
s
e
w
i
t
h
o
t
h
e
r
h
e
p
a
t
o
b
i
l
i
a
r
y
a
g
e
n
t
s
,
i
n
c
l
u
d
i
n
g
i
t
s
p
a
r
e
n
t
U
D
C
A
/
u
r
s
o
d
i
o
l
,
o
v
e
r
l
a
p
s
m
e
c
h
a
n
i
s
t
i
c
a
l
l
y
a
n
d
s
h
o
u
l
d
b
e
m
e
d
i
c
a
l
l
y
s
u
p
e
r
v
i
s
e
d
.
B
e
c
a
u
s
e
i
t
a
l
t
e
r
s
b
i
l
e
f
l
o
w
a
n
d
b
i
l
e
-
a
c
i
d
c
o
m
p
o
s
i
t
i
o
n
,
e
f
f
e
c
t
s
o
n
t
h
e
a
b
s
o
r
p
t
i
o
n
o
f
f
a
t
-
s
o
l
u
b
l
e
d
r
u
g
s
a
n
d
v
i
t
a
m
i
n
s
a
r
e
p
l
a
u
s
i
b
l
e
.
I
n
t
h
e
A
L
S
c
o
n
t
e
x
t
i
t
w
a
s
d
e
l
i
b
e
r
a
t
e
l
y
c
o
-
f
o
r
m
u
l
a
t
e
d
w
i
t
h
s
o
d
i
u
m
p
h
e
n
y
l
b
u
t
y
r
a
t
e
(
A
M
X
0
0
3
5
)
,
a
d
e
s
i
g
n
e
d
c
o
m
b
i
n
a
t
i
o
n
r
a
t
h
e
r
t
h
a
n
a
n
i
n
c
i
d
e
n
t
a
l
i
n
t
e
r
a
c
t
i
o
n
.
A
n
y
o
n
e
o
n
p
r
e
s
c
r
i
p
t
i
o
n
m
e
d
i
c
a
t
i
o
n
,
p
a
r
t
i
c
u
l
a
r
l
y
f
o
r
l
i
v
e
r
,
b
i
l
i
a
r
y
,
o
r
m
e
t
a
b
o
l
i
c
d
i
s
e
a
s
e
,
s
h
o
u
l
d
r
e
v
i
e
w
T
U
D
C
A
w
i
t
h
a
c
l
i
n
i
c
i
a
n
o
r
p
h
a
r
m
a
c
i
s
t
f
i
r
s
t
.

Who should avoid it

Pregnant or breastfeeding individuals (no TUDCA-specific safety data)
People with biliary obstruction, acute gallbladder disease, or cholestasis of undetermined cause without clinician oversight
Anyone treating a diagnosed liver disease who is using TUDCA in place of, rather than alongside, proper medical evaluation
People taking bile-acid sequestrants or other hepatobiliary drugs without medical guidance
Anyone expecting it to treat ALS, Alzheimer's, Parkinson's or metabolic disease based on preclinical or withdrawn-drug evidence

How it is commonly combined

In the supplement market TUDCA is commonly stacked with other "liver support" ingredients such as milk thistle (silymarin), NAC, glycine, and choline, and it is frequently marketed to users of hepatotoxic compounds (for example oral anabolic steroids or SARMs) as on-cycle liver support. It is important to be clear that there is no robust human evidence that TUDCA prevents or reverses drug-induced liver injury from such compounds, and using it as a rationale to take hepatotoxic substances is not supported. The one genuinely studied combination is pharmaceutical: TUDCA (as taurursodiol) with sodium phenylbutyrate in AMX0035, which was a designed drug, not a consumer stack, and whose confirmatory ALS trial failed. Treat consumer stacking claims as marketing, not evidence.

Legal & regulatory. In the United States TUDCA is not an FDA-approved drug. It is widely sold as a dietary supplement for "liver support," but its status as a lawful dietary ingredient is not clean: unlike its parent compound UDCA (ursodiol), which is an FDA-approved prescription drug for gallstone dissolution and primary biliary cholangitis, TUDCA has no US marketing approval, and the FDA has issued import alerts on bulk TUDCA powder from China as potentially misbranded/adulterated. It is not scheduled or otherwise controlled. Abroad, TUDCA has been marketed as a pharmaceutical for cholestatic liver disease (e.g., Tudcabil in Italy, and formulations in China and South Korea). As a taurine conjugate of UDCA, it is investigated as a drug ingredient (notably one half of the AMX0035 combination), not merely a supplement. Informational only; this is not legal or medical advice.

Quality & harm reduction

T
U
D
C
A
i
s
s
o
l
d
a
s
a
b
u
l
k
-
d
e
r
i
v
e
d
w
h
i
t
e
p
o
w
d
e
r
,
m
o
s
t
o
f
i
t
s
y
n
t
h
e
s
i
z
e
d
o
r
s
e
m
i
-
s
y
n
t
h
e
s
i
z
e
d
(
n
o
l
e
g
i
t
i
m
a
t
e
m
o
d
e
r
n
p
r
o
d
u
c
t
u
s
e
s
a
c
t
u
a
l
b
e
a
r
b
i
l
e
)
.
B
e
c
a
u
s
e
i
t
i
s
n
o
t
m
a
n
u
f
a
c
t
u
r
e
d
t
o
d
r
u
g
s
t
a
n
d
a
r
d
s
i
n
t
h
e
U
S
s
u
p
p
l
e
m
e
n
t
c
h
a
n
n
e
l
,
a
n
d
b
e
c
a
u
s
e
t
h
e
F
D
A
h
a
s
f
l
a
g
g
e
d
i
m
p
o
r
t
e
d
C
h
i
n
e
s
e
b
u
l
k
T
U
D
C
A
a
s
p
o
t
e
n
t
i
a
l
l
y
m
i
s
b
r
a
n
d
e
d
,
l
a
b
e
l
-
t
o
-
c
o
n
t
e
n
t
a
c
c
u
r
a
c
y
v
a
r
i
e
s
w
i
d
e
l
y
b
e
t
w
e
e
n
b
r
a
n
d
s
.
M
e
a
n
i
n
g
f
u
l
q
u
a
l
i
t
y
s
i
g
n
a
l
s
a
r
e
a
C
e
r
t
i
f
i
c
a
t
e
o
f
A
n
a
l
y
s
i
s
s
h
o
w
i
n
g
i
d
e
n
t
i
t
y
a
n
d
a
s
s
a
y
(
t
a
r
g
e
t
p
u
r
i
t
y
t
y
p
i
c
a
l
l
y
s
t
a
t
e
d
a
t
9
8
%
+
)
,
t
h
i
r
d
-
p
a
r
t
y
t
e
s
t
i
n
g
f
o
r
h
e
a
v
y
m
e
t
a
l
s
a
n
d
m
i
c
r
o
b
i
a
l
c
o
n
t
a
m
i
n
a
t
i
o
n
,
a
n
d
a
m
a
n
u
f
a
c
t
u
r
e
r
t
h
a
t
d
i
s
c
l
o
s
e
s
t
h
e
r
a
w
-
m
a
t
e
r
i
a
l
s
o
u
r
c
e
.
D
i
s
t
i
n
g
u
i
s
h
i
t
f
r
o
m
U
D
C
A
(
u
r
s
o
d
i
o
l
)
:
t
h
e
y
a
r
e
r
e
l
a
t
e
d
b
u
t
n
o
t
i
n
t
e
r
c
h
a
n
g
e
a
b
l
e
,
a
n
d
p
h
a
r
m
a
c
e
u
t
i
c
a
l
u
r
s
o
d
i
o
l
i
s
a
r
e
g
u
l
a
t
e
d
d
r
u
g
w
h
i
l
e
T
U
D
C
A
i
s
n
o
t
.
I
n
f
o
r
m
a
t
i
o
n
a
l
o
n
l
y
;
P
e
p
t
r
o
p
i
x
d
o
e
s
n
o
t
s
e
l
l
t
h
i
s
c
o
m
p
o
u
n
d
.

Safer, legal alternative we recommend

Liver Let Live. For liver and metabolic support, our Liver Support formula is a legal supplement option covering a similar goal.

See our recommended pick

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is TUDCA the same as UDCA / ursodiol?

No. TUDCA is the taurine-conjugated form of UDCA (ursodeoxycholic acid). They are chemically related and share hepatobiliary effects, but they are not interchangeable. UDCA/ursodiol is an FDA-approved prescription drug; TUDCA is not approved in the US and is sold as a supplement.

Does TUDCA actually protect the liver?

The clearest human evidence is in cholestatic liver disease (impaired bile flow, such as primary biliary cholangitis), where small studies show it improves liver enzymes comparably to UDCA. Broader 'detox' or general liver-protection claims, including protecting against damage from anabolic steroids or other hepatotoxic compounds, are not supported by robust human trials.

Didn't TUDCA get approved for ALS?

Not on its own. TUDCA (as taurursodiol) was one half of the two-drug combination AMX0035. That product (Relyvrio/Albrioza) received approval after a positive phase 2 trial, but the larger phase 3 PHOENIX trial was negative and the manufacturer withdrew it in 2024. TUDCA alone is not an established ALS treatment.

Is TUDCA safe?

In trials it has generally been well tolerated, with mostly mild gastrointestinal effects such as diarrhea and nausea. But long-term safety data are limited, it should be avoided in pregnancy and breastfeeding, and anyone with liver, gallbladder, or biliary disease should not self-treat. This is informational only, not medical advice.

How much TUDCA is used in studies?

Published human studies span roughly 500 mg/day up to about 1,750-2,000 mg/day for defined periods. We do not provide dosing guidance. If you are considering TUDCA, discuss it with a qualified clinician who can weigh your liver status, medications, and reason for use.

Is the TUDCA sold online legitimate?

Quality varies. Much bulk TUDCA is imported from China, and the FDA has flagged some of that material as potentially misbranded. If evaluating a product, look for a Certificate of Analysis showing identity and purity (often stated at 98%+) plus third-party testing for heavy metals and contaminants. Peptropix does not sell this compound; this is reference information only.

References & further reading

PubMed: tauroursodeoxycholic acid endoplasmic reticulum stress chemical chaperone unfolded protein response
PubMed: tauroursodeoxycholate bile acid chaperoning activity molecular cellular effects therapeutic perspectives review
PubMed: tauroursodeoxycholic acid insulin sensitivity obese hepatic muscle Kars
PubMed: sodium phenylbutyrate taurursodiol AMX0035 amyotrophic lateral sclerosis CENTAUR PHOENIX trial
ClinicalTrials.gov: tauroursodeoxycholic acid TUDCA liver insulin resistance